Esmirtazapine
Small molecule targets HRH1, HTR2A, HTR2C via inhibition
Trials 10
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Esmirtazapine | “This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001...” NCT00610675 ↗ |
| Known as | (s)-6-azamianserin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366933 ↗ |
| Known as | (s)-mirtazapine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366933 ↗ |
| Known as | (s)-org 3770 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366933 ↗ |
| Known as | Esmirtazapina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366933 ↗ |
| Known as | ESMIRTAZAPINE MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366933 ↗ |
| Known as | MK-8265 | “randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and tolerability of long-term treatment with...” NCT00561574 ↗1“treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo” NCT00631657 ↗ |
| Known as | Org 50081 | “This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001...” NCT00610675 ↗5“Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)” NCT00750919 ↗ “The maleic acid salt of Org 4420, code name Org 50081 (esmirtazapine), was selected for development in the treatment of insomnia.” NCT00561574 ↗ “The maleic acid salt of Org 4420, code name Org 50081, known as Esmirtazapine, was” NCT00561821 ↗ “treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo” NCT00631657 ↗ |
| Known as | ORG-44-20 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1366933 ↗ |
| Known as | SCH 900265 | “randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and tolerability of long-term treatment with...” NCT00561574 ↗1“treatment with esmirtazapine (Org 50081, SCH 900265, MK-8265) compared to placebo” NCT00631657 ↗ |
| Action | Inhibit | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL1366933 ↗3“Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL1366933 ↗ “a high-affinity antagonist at 5-HT2A” PMID 26047890 ↗ Mar 2015 “Histamine H1 receptor antagonist” CHEMBL1366933 ↗ |
| Modality | Small molecule | — CHEMBL1366933 ↗ |
| Route | Oral | “tablets for oral use” NCT00482612 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL1366933 ↗ |
| Target | HTR2A | “Serotonin 2a (5-HT2a) receptor antagonist” CHEMBL1366933 ↗ |
| Target | HTR2C | “Serotonin 2c (5-HT2c) receptor antagonist” CHEMBL1366933 ↗ |